Solange Peters, MD, PhD

Dr Johnson reviews data from the ARC-7 trial investigating an anti-PD-L1 plus anti-TGIT combination treatment for advanced NSCLC.

Drs Peters and Velcheti provide an overview of the role of anti-TGIT immunotherapies in NSCLC treatment.

Solange Peters, MD, explains the currently available treatment options for patients with advanced NSCLC after progression on immunotherapy.

Melissa Johnson, MD, explains the design and outcomes of the multi-arm POSEIDON study, which featured a combination of 4 agents for the treatment of advanced NSCLC.

Key opinion leaders discuss data from the EMPOWER-Lung-3 study investigating the use of cemiplimab plus chemotherapy in both squamous and non-squamous NSCLC.

Dr Velcheti reviews data on the chemoimmunotherapy treatment of squamous NSCLC from the KEYNOTE-407 study.

Dr Vamsidhar Velcheti explains the 4-year data updates to the CheckMate 227 trial, which investigated PD-L1 monotherapy plus chemotherapy for advanced NSCLC.

Drs Peters and Johnson discuss recent updates in the treatment of advanced NSCLC with single- and dual-agent immunotherapy regimens.

Dr Melissa Johnson and Dr Myung-Ju Ahn emphasize the importance of a multidisciplinary approach to treatment and biomarker testing for patients with early-stage NSCLC.

Closing out their discussion, the panel highlights investigational therapies in NSCLC to look out for.

The panel discusses the challenges of treatment and unmet needs of HER2-mutated or amplified NSCLC.

Drs Anil Vachani and Mark Socinski continue their discussion of anti-HER2 therapies by mentioning some of the unmet needs in NSCLC treatment despite the range of available treatment options.

Vamsidhar Velcheti, MD, summarizes recent data on adjuvant immunotherapy treatment in resectable NSCLC.

Dr Myung-Ju Ahn describes the unique design and outcomes of the NEOCoast study that is evaluating immunotherapy regimens in the neoadjuvant and adjuvant settings.

Drs Socinski and Vachani explain the typical adverse events seen with anti-HER2 therapies and how to manage them.

Drs Timothy Craig Allen and Ticiana Leal review the HER2-targeted therapies in NSCLC, including mechanism of action and supportive clinical trial data.

Drs Vamsidhar Velcheti and Solange Peters discuss the optimum length for immunotherapy treatment in resectable NSCLC, highlighting the issue of payer authorizations.

Oncologists explain data from the NADIM II and AEGAN clinical trials investigating treatments for neoadjuvant immunotherapy in resectable NSCLC.

Solange Peters, MD, PhD, presents the case of a 72-year-old man with HER2-amplified NSCLC and starts a discussion on the recommended treatment plans.

Dr Mark A Socinski reviews the currently available treatment options for NSCLC, including targeted therapies.

Anil Vachani, MD, MS, explains whether he orders biomarker testing for all patients with HER2-mutated NSCLC.

Drs Allen and Socinski discussion the role of HER2 alterations in NSCLC and how it differs from breast cancer.

Myung-Ju Ahn, MD, summarizes the role of neoadjuvant immunotherapy in early-stage NSCLC treatment.

Melissa Johnson, MD, and Solange Peters, MD, review the available treatment options for stage I – III non-small cell lung cancer (NSCLC) and how the ESMO guidelines of patient management differ from the NCCN guidelines.

Dr Solange Peters shares the molecular testing results for the patient in the presented clinical scenario.

Mark A. Socinski, MD, debates the merits of liquid versus tissue tumor biopsies in NSCLC biomarker testing.

Timothy Craig Allen, MD, JD, FCAP, explains how he approaches biomarker testing in NSCLC and what testing he would have ordered in the presented scenario.

A panel of experts discusses the testing and targeting of HER2 in non-small cell lung cancer (NSCLC) and the impact of recent clinical trial data on treatment selection.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Dr Solange Peters reviews data from POSEIDON on combination durvalumab, tremelimumab, and chemotherapy in patients with metastatic non-small cell lung cancer (mNSCLC) that were recently presented at the 2022 World Conference on Lung Cancer.